サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541386

血液悪性腫瘍市場レポート：タイプ、治療法、エンドユーザー、地域別、2024～2032年

Hematologic Malignancies Market Report by Type, Therapy, End User, and Region 2024-2032
出版日: | 発行: IMARC | ページ情報: 英文 136 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.86円
血液悪性腫瘍市場レポート：タイプ、治療法、エンドユーザー、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の血液悪性腫瘍市場規模は2023年に603億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに1,224億米ドルに達し、2024～2032年の間に7.9%の成長率（CAGR）を示すと予測しています。血液がんの有病率の増加、遺伝子プロファイルに合わせた標的療法や免疫療法の採用の増加、血液がんの新規治療に焦点を当てたバイオ医薬品パイプラインの拡大は、市場の成長を促進する主要要因の一部です。

血液悪性腫瘍市場分析

主要市場促進要因高齢化社会と相まって、血液悪性腫瘍の罹患率が上昇していることが、血液悪性腫瘍治療の需要を牽引しています。さらに、早期診断に対する意識の高まりや診断方法の改善も市場成長に寄与しています。

主要市場動向：標的治療、免疫療法、個別化医療における革新は、治療の選択肢を変え、転帰を改善し、血液がん患者の副作用を軽減しており、血液悪性腫瘍市場の収益を促進する重要な要因のひとつです。

競合情勢：世界市場で事業を展開する大手企業には、AbbVie Inc.、AstraZeneca plc、Bristol-Myers Squibb Company、Eli Lilly and Company、F. Hoffmann-La Roche Ltd、GlaxoSmithKline plc、Johnson &Johnson、Merck &Co.Inc.、Novartis AG、Pfizer Inc.、Sanofi S.A.、Takeda Pharmaceutical Company Limitedなどです。

地理的動向：血液悪性腫瘍市場は世界的に力強い成長を示しています。北米では、高度な医療インフラと高い罹患率が成長の要因となっています。欧州は研究開発に多額の投資を行っています。アジア太平洋は、医療費の増加と先進治療へのアクセスの改善により急速に台頭しており、市場の拡大を後押ししています。

課題と機会：血液悪性腫瘍市場は、高い治療費、複雑な疾患生物学、個別化治療の必要性などの課題に直面しています。しかし、患者の予後を改善し、効果的で個別化されたがん治療ソリューションに対する需要の高まりに対応するための標的療法、免疫療法、診断技術の進歩には機会が存在します。

血液悪性腫瘍市場傾向

血液がんの有病率の上昇

血液がんの罹患率の上昇と新たな治療法の開発が血液悪性腫瘍市場の成長を牽引しています。Globocan 2020によると、白血病の推定罹患率はアジアで最も高く、2020年に23万650例が診断され、次いで欧州の10万20例、北米の6万7,784例となっています。このように、世界的に白血病の罹患率が高いことが、血液悪性腫瘍市場の成長を牽引すると予想されます。同様に、Global Cancer Observatoryによると、2020年には北米地域で6万7,784例近くの白血病と推定3万5,318例の多発性骨髄腫が報告されています。白血病リンパ腫協会によると、2021年には、米国で白血病を患うか寛解状態にある人は合わせて39万7,501人と推定されます。したがって、市場における血液がん患者の顕著な増加は、予測期間にわたって血液悪性腫瘍市場の値を推進すると予想されます。

製品上市、パートナーシップ、提携の増加

数多くの企業が、市場での存在感を高めるために、新製品の上市、パートナーシップの形成、協力関係の促進、M&Aなど、多様な戦略的イニシアチブを実施しています。これは、血液悪性腫瘍市場の展望にプラスの影響を与えています。例えば、2020年10月、AstraZeneca Pharma India社は、様々なタイプの白血病（白血病（CLL）と小リンパ球性リンパ腫）の治療に使用されるアカラブルチニブ100mgカプセルをCalquenceのブランド名で発売すると発表しました。同様に2024年1月、タタ記念病院はインド初の白血病用経口化学療法薬を開発しました。この画期的な開発は、がん治療、特に急性リンパ芽球性白血病（ALL）のような血液悪性腫瘍に革命をもたらし、従来の錠剤に代わる、より正確で子どもにやさしい治療法を記載しています。このような技術革新は、今後数年間で血液悪性腫瘍市場の需要を増大させると予測されます。

製品認可の増加

様々な関係規制当局が血液悪性腫瘍治療を承認する動きが加速しており、市場全体に明るい展望をもたらしています。例えば、米国FDAは2020年9月、Bristol Myers Squibbのアザシチジン（オヌレグ）300mg錠、CC-486を、急性骨髄性白血病の成人患者の治療を継続するために承認しました。同様に2021年3月、サノフィSAは再発または難治性の多発性骨髄腫患者を対象に、サルクリサ（イサツキシマブ）とカルフィルゾミブとデキサメタゾンとの併用療法の米国FDA承認を取得しました。これに伴い、2021年2月、TG Therapeutics Inc.は、再発・難治性の辺縁帯リンパ腫（MZL）成人患者と再発・難治性の濾胞性リンパ腫（FL）成人患者の治療として、1日1回経口投与のホスホイノシチド3キナーゼ（PI3K）デルタとカゼインキナーゼ1（CK1）イプシロン阻害剤であるUKONIQ（ウンブラリシブ）について、米国FDAの迅速承認を取得しました。血液がんの治療として承認された薬剤の数が大幅に増加していることが、血液悪性腫瘍市場の値を押し上げています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の血液悪性腫瘍市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 白血病
  • リンパ腫
  • 多発性骨髄腫
  • その他

第7章 市場内訳：治療法別

  • 化学療法
  • 放射線療法
  • 免疫療法
  • 幹細胞移植
  • その他

第8章 市場内訳：エンドユーザー別

  • 病院
  • 診断センター
  • 研究センター
  • その他

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Merck & Co. Inc
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Takeda Pharmaceutical Company Limited
図表

List of Figures

  • Figure 1: Global: Hematologic Malignancies Market: Major Drivers and Challenges
  • Figure 2: Global: Hematologic Malignancies Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hematologic Malignancies Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Hematologic Malignancies Market: Breakup by Type (in %), 2023
  • Figure 5: Global: Hematologic Malignancies Market: Breakup by Therapy (in %), 2023
  • Figure 6: Global: Hematologic Malignancies Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Hematologic Malignancies Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Hematologic Malignancies (Leukemia) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Hematologic Malignancies (Leukemia) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Hematologic Malignancies (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Hematologic Malignancies (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Hematologic Malignancies (Multiple Myeloma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Hematologic Malignancies (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Hematologic Malignancies (Other Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Hematologic Malignancies (Other Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Hematologic Malignancies (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Hematologic Malignancies (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Hematologic Malignancies (Radiotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Hematologic Malignancies (Radiotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Hematologic Malignancies (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Hematologic Malignancies (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Hematologic Malignancies (Stem Cell Transplantation) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Hematologic Malignancies (Stem Cell Transplantation) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Hematologic Malignancies (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Hematologic Malignancies (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: Global: Hematologic Malignancies (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: Global: Hematologic Malignancies (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: Global: Hematologic Malignancies (Diagnostics Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: Global: Hematologic Malignancies (Diagnostics Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Global: Hematologic Malignancies (Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Global: Hematologic Malignancies (Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Global: Hematologic Malignancies (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Global: Hematologic Malignancies (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: North America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: North America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: United States: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: United States: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: Canada: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: Canada: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: Asia-Pacific: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: Asia-Pacific: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: China: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: China: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Japan: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Japan: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: India: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: India: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: South Korea: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: South Korea: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Australia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Australia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: Indonesia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: Indonesia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Europe: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Europe: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Germany: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Germany: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: France: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: France: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: United Kingdom: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: United Kingdom: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Italy: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Italy: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Spain: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Spain: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Russia: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Russia: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Latin America: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Latin America: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 74: Brazil: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 75: Brazil: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 76: Mexico: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 77: Mexico: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 78: Others: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 79: Others: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 80: Middle East and Africa: Hematologic Malignancies Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 81: Middle East and Africa: Hematologic Malignancies Market: Breakup by Country (in %), 2023
  • Figure 82: Middle East and Africa: Hematologic Malignancies Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Global: Hematologic Malignancies Industry: SWOT Analysis
  • Figure 84: Global: Hematologic Malignancies Industry: Value Chain Analysis
  • Figure 85: Global: Hematologic Malignancies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hematologic Malignancies Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hematologic Malignancies Market Forecast: Breakup by Type (in Million US$), 2024-2032
  • Table 3: Global: Hematologic Malignancies Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 4: Global: Hematologic Malignancies Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Hematologic Malignancies Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Hematologic Malignancies Market: Competitive Structure
  • Table 7: Global: Hematologic Malignancies Market: Key Players
目次
Product Code: SR112024A4133

The global hematologic malignancies market size reached US$ 60.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 122.4 Billion by 2032, exhibiting a growth rate (CAGR) of 7.9% during 2024-2032. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.

Hematologic Malignancies Market Analysis:

Major Market Drivers: The rising incidence of hematologic malignancies, coupled with an aging population, is driving demand for hematologic malignancy drugs. Additionally, the growing awareness about early diagnosis, along with improving diagnostic modalities, is also contributing to market growth.

Key Market Trends: Innovations in targeted therapies, immunotherapy, and personalized medicine, which are transforming treatment options, improving outcomes, and reducing side effects for patients with hematologic cancers, refer to one of the significant factors catalyzing the hematologic malignancies market revenue.

Competitive Landscape: Some of the leading companies operating in the global market include AbbVie Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited, among many others.

Geographical Trends: The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Challenges and Opportunities: The hematologic malignancies market faces challenges such as high treatment costs, complex disease biology, and the need for personalized therapies. However, opportunities exist in advancing targeted therapies, immunotherapies, and diagnostic technologies to improve patient outcomes and meet the growing demand for effective and personalized cancer care solutions.

Hematologic Malignancies Market Trends:

Rising Prevalence of Blood Cancer

Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.

Growing Number of Product Launches, Partnerships, and Collaborations

Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.

Increasing Product Approvals

Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.

Global Hematologic Malignancies Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global hematologic malignancies market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on type, therapy, and end user.

Breakup by Type:

Leukemia

Lymphoma

Multiple Myeloma

Others

The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.

Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.

Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.

Breakup by Therapy:

Chemotherapy

Radiotherapy

Immunotherapy

Stem Cell Transplantation

Others

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiotherapy, immunotherapy, stem cell transplantation, and others.

As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.

Breakup by End User:

Hospitals

Diagnostics Centers

Research Centers

Others

The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.

Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.

Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.

The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.

Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the detailed profiles of the following key players:

AbbVie Inc.

AstraZeneca plc

Bristol-Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

GlaxoSmithKline plc

Johnson & Johnson

Merck & Co. Inc

Novartis AG

Pfizer Inc.

Sanofi S.A.

Takeda Pharmaceutical Company Limited

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Global Hematologic Malignancies Market News:

June 2024: The University of Cincinnati Cancer Center launched a new treatment center dedicated specifically to blood cancers. It is the university's first state-of-the-art center devoted to blood cancer care in the United States.

June 2024: Fortis inaugurated a state-of-the-art facility for the specialized treatment of blood cancers and disorders.

January 2024: Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets.

Key Questions Answered in This Report:

  • How big is the hematologic malignancies market?
  • How has the global hematologic malignancies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global hematologic malignancies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hematologic malignancies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hematologic Malignancies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Leukemia
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Multiple Myeloma
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiotherapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Stem Cell Transplantation
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Diagnostics Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Research Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 AstraZeneca plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bristol-Myers Squibb Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Eli Lilly and Company
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 F. Hoffmann-La Roche Ltd
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 GlaxoSmithKline plc
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Johnson & Johnson
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Merck & Co. Inc
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Novartis AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis